Nykode Therapeutics ASA
OSE:NYKD
Intrinsic Value
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. [ Read More ]
The intrinsic value of one NYKD stock under the Base Case scenario is hidden NOK. Compared to the current market price of 14.67 NOK, Nykode Therapeutics ASA is hidden .
Valuation Backtest
Nykode Therapeutics ASA
Run backtest to discover the historical profit from buying and selling NYKD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Nykode Therapeutics ASA
| Current Assets | 165.7m |
| Cash & Short-Term Investments | 162.6m |
| Receivables | 3.1m |
| Non-Current Assets | 42.5m |
| PP&E | 10.5m |
| Intangibles | 70k |
| Other Non-Current Assets | 31.9m |
| Current Liabilities | 20.6m |
| Accounts Payable | 5.5m |
| Other Current Liabilities | 15.1m |
| Non-Current Liabilities | 16.3m |
| Long-Term Debt | 4.3m |
| Other Non-Current Liabilities | 12m |
Earnings Waterfall
Nykode Therapeutics ASA
|
Revenue
|
12.9m
USD
|
|
Operating Expenses
|
-69.3m
USD
|
|
Operating Income
|
-56.4m
USD
|
|
Other Expenses
|
21.2m
USD
|
|
Net Income
|
-35.2m
USD
|
Free Cash Flow Analysis
Nykode Therapeutics ASA
NYKD Profitability Score
Profitability Due Diligence
Nykode Therapeutics ASA's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Nykode Therapeutics ASA's profitability score is hidden . The higher the profitability score, the more profitable the company is.
NYKD Solvency Score
Solvency Due Diligence
Nykode Therapeutics ASA's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Nykode Therapeutics ASA's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NYKD Price Targets Summary
Nykode Therapeutics ASA
According to Wall Street analysts, the average 1-year price target for NYKD is 39.99 NOK with a low forecast of 28.28 NOK and a high forecast of 73.32 NOK.
Shareholder Return
NYKD Price
Nykode Therapeutics ASA
| Average Annual Return | -9.72% |
| Standard Deviation of Annual Returns | 48.25% |
| Max Drawdown | -86% |
| Market Capitalization | 4.8B NOK |
| Shares Outstanding | 326 546 444 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Contact
IPO
Employees
Officers
The intrinsic value of one NYKD stock under the Base Case scenario is hidden NOK.
Compared to the current market price of 14.67 NOK, Nykode Therapeutics ASA is hidden .
You don't have any saved screeners yet
